My sense is the safety data form the underpinnings of phase 1 exemptions in other trials where safety is a huge focus, and are leveraged for package insert type material to doctors in upcoming trials to inform them…and prospective trial participants…of risk/benefit. It may not be a hard stop but it’s a healthy move to put it in the rear view mirror.